The U.S. Food and Drug Administration’s full approval of the Pfizer-BioNTech coronavirus vaccine for people 16 and older could embolden more employers to require vaccination and certainly weakens employees’ attempts to litigate the issue.
Despite the win for employers, attorneys continue to advise treading lightly when considering a vaccine mandate.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]